hims semaglutide out of stock & Hers Tumbles 12% due to GLP-1 supplier concerns- Fast Company Hims & Hers shares fall

The solution for efficient fill & finish performance and minimized TCO

With a powerful blend of 7 probiotic strains, including a resilient spore-forming strain, this formula is designed to support regularity, ease, and digestive flow so you can feel balanced again, without the guesswork

PlexusDx explains the performance implications, hydration needs, and training adjustments required when starting GLP-1 therapy

GLP1 therapy is now approved for adolescents with type 2 diabetes and obesity

As the semaglutide patent expiries begin in 2026 across key global markets, Indian pharma companies are racing to capture the opportunity amid rising competition, falling prices & regulatory uncertainty Ekta Bhatra breaks down who stands to gain, the risks ahead, & how GLP-1 drugs could drive the next phase of pharma growth